Hepatitis C virus (HCV) encodes mechanisms to evade the multilayered antiviral actions of the host immune system. Great progress has been made in elucidating the strategies HCV employs to downregulate interferon (IFN) production, impede IFN signaling transduction, and impair IFN-stimulated gene (ISG) expression. However, there is a limited understanding of the mechanisms governing how viral proteins counteract the antiviral functions of downstream IFN effectors due to the lack of an efficient approach to identify such interactions systematically. To study the mechanisms by which HCV antagonizes the IFN responses, we have developed a high-throughput profiling platform that enables mapping of HCV sequences critical for anti-IFN function at high resolution. Genome-wide profiling performed with a 15-nt insertion mutant library of HCV showed that mutations in the p7 region conferred high levels of IFN sensitivity, which could be alleviated by the expression of WT p7 protein. This finding suggests that p7 protein of HCV has an immune evasion function. By screening a liver-specific ISG library, we identified that IFI6-16 significantly inhibits the replication of p7 mutant viruses without affecting WT virus replication. In contrast, knockout of IFI6-16 reversed the IFN hypersensitivity of p7 mutant virus. In addition, p7 was found to be coimmunoprecipitated with IFI6-16 and to counteract the function of IFI6-16 by depolarizing the mitochondria potential. Our data suggest that p7 is a critical immune evasion protein that suppresses the antiviral IFN function by counteracting the function of IFI6-16.HCV | innate immune evasion mechanism | IF6-16 antiviral function | high-throughput mutagenesis | p7 ion channel protein W ith an estimated 170 million people persistently infected worldwide, hepatitis C virus (HCV) has emerged as a major cause of human liver diseases, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma (1, 2). Despite the recent breakthroughs in the development of HCV direct antiviral agents (DAAs) aiming to cure chronic HCV infection, emerging resistant mutations and drug-resistant polymorphisms at the baseline of treatments remain major challenges to eradicate HCV (3-8). In addition, the high cost of these DAAs limits their accessibility to the majority of patients worldwide. Therefore, HCV eradication is still heavily dependent on the development of an effective preventative vaccine (9). Understanding how the virus evades the immune system, which results in a poor immune response of the infected host against the virus, will provide important information for immune therapy and vaccine development.